MRTX
- Mirati Therapeutics, Inc.
()
Overview
Company Summary
Mirati Therapeutics, Inc. is a biotechnology company that focuses on the development of targeted oncology therapeutics. The company is dedicated to transforming the treatment of cancer by developing innovative drugs that address unmet medical needs.
Mirati Therapeutics employs a precision medicine approach, which involves identifying specific genetic and molecular alterations present in a patient's tumor. This helps them design therapies that target these specific alterations, thereby increasing the likelihood of an effective treatment.
The company has a pipeline of investigational drugs that are being developed for various types of cancers, including lung cancer, colorectal cancer, and solid tumors. Their lead drug candidate, adagrasib (formerly known as MRTX849), is designed to target certain genetic mutations in non-small cell lung cancer and colorectal cancer.
Mirati Therapeutics leverages its expertise in drug discovery, translational research, and clinical development to advance its pipeline. They collaborate with academic institutions and strategic partners to enhance their capabilities and develop novel cancer therapies. The company's goal is to develop innovative treatments that improve patient outcomes and potentially change the way cancer is treated.